Secreted proteins encoded by super enhancer-driven genes could be promising biomarkers for early detection of esophageal squamous cell carcinoma

Pastrez, 2017, The relation of HPV infection and expression of p53 and p16 proteins in esophageal squamous cells carcinoma, J Cancer, 8, 1062, 10.7150/jca.17080 Bray, 2021, Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Pennathur, 2013, Esophageal carcinoma, Lancet, 381, 400, 10.1016/S0140-6736(12)60643-6 Enzinger, 2003, Esophageal cancer, N Engl J Med, 349, 2241, 10.1056/NEJMra035010 Wang, 2014, Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma, World J Gastroenterol, 20, 18397, 10.3748/wjg.v20.i48.18397 Gaddam, 2013, Endoscopic tumor diagnosis and treatment, Gastrointest Endosc, 78, 421, 10.1016/j.gie.2013.06.023 di Pietro, 2018, Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy, Gastroenterology, 154, 421, 10.1053/j.gastro.2017.07.041 Sturgeon, 2009, Serum tumor markers: how to order and interpret them, BMJ, 339, b3527, 10.1136/bmj.b3527 Kosugi, 2004, Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients, World J Surg, 28, 680, 10.1007/s00268-004-6865-y Mroczko, 2008, The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients, Clin Chim Acta, 389, 61, 10.1016/j.cca.2007.11.023 Nakamura, 2017, CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus, Dis Esophagus, 11, 35, 10.1093/dote/11.1.35 Whyte, 2013, Master transcription factors and mediator establish super-enhancers at key cell identity genes, Cell, 153, 307, 10.1016/j.cell.2013.03.035 Loven, 2013, Selective inhibition of tumor oncogenes by disruption of super-enhancers, Cell, 153, 320, 10.1016/j.cell.2013.03.036 Hnisz, 2013, Super-enhancers in the control of cell identity and disease, Cell, 155, 934, 10.1016/j.cell.2013.09.053 Sengupta, 2017, Super-enhancer-driven transcriptional dependencies in cancer, Trends Cancer, 3, 269, 10.1016/j.trecan.2017.03.006 Jiang, 2017, Targeting super-enhancer-associated oncogenes in esophageal squamous cell carcinoma, Gut, 66, 1358, 10.1136/gutjnl-2016-311818 Ropri, 2021, Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer, Breast Cancer Res, 23, 101, 10.1186/s13058-021-01479-8 Wang, 2020, The emerging role of super enhancer-derived noncoding RNAs in human cancer, Theranostics, 10, 11049, 10.7150/thno.49168 Xie, 2018, Super-enhancer-driven long non-coding RNA LINC01503, regulated by TP63, is over-expressed and oncogenic in squamous cell carcinoma, Gastroenterology, 154, 2137, 10.1053/j.gastro.2018.02.018 Jiang, 2018, Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression, Nat Commun, 9, 3619, 10.1038/s41467-018-06081-9 Rice, 2017, Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 304, 10.3322/caac.21399 Xu, 2014, Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma, Am J Gastroenterol, 109, 36, 10.1038/ajg.2013.384 Shen, 2012, Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study, Lancet Oncol, 13, 817, 10.1016/S1470-2045(12)70233-4 Kim, 2022, An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B, J Hepatol, 76, 311, 10.1016/j.jhep.2021.09.025 Luan, 2023, A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study, eClinicalMedicine, 61, 10.1016/j.eclinm.2023.102041 Khodami, 2020, Retraction note: molecular phylogeny and revision of copepod orders (Crustacea: copepoda), Sci Rep, 10, 10.1038/s41598-020-74404-2 Ye, 2021, Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis, Nat Commun, 12, 4457, 10.1038/s41467-021-24813-2 He, 2019, Targeting super-enhancers as a therapeutic strategy for cancer treatment, Front Pharmacol, 10, 361, 10.3389/fphar.2019.00361 Hao, 2020, Role of EFNA1 in tumorigenesis and prospects for cancer therapy, Biomed Pharmacother, 130, 10.1016/j.biopha.2020.110567 Nakamura, 2005, EPHA2/EFNA1 expression in human gastric cancer, Cancer Sci, 96, 42, 10.1111/j.1349-7006.2005.00007.x Zhang, 2021, Effects of EFNA1 on cell phenotype and prognosis of esophageal carcinoma, World J Surg Oncol, 19, 242, 10.1186/s12957-021-02362-8 Nasreen, 2007, Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM), Cancer Lett, 258, 215, 10.1016/j.canlet.2007.09.005 Beauchamp, 2012, Ephs and ephrins in cancer: ephrin-A1 signalling, Semin Cell Dev Biol, 23, 109, 10.1016/j.semcdb.2011.10.019 Cui, 2010, EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma, Int J Cancer, 126, 940, 10.1002/ijc.24798 Lafleur, 2005, Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13, Int J Cancer, 114, 544, 10.1002/ijc.20763 Curran, 2000, Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis, Eur J Cancer, 36, 1621, 10.1016/S0959-8049(00)00156-8 Deryugina, 2006, Matrix metalloproteinases and tumor metastasis, Cancer Metastasis Rev, 25, 9, 10.1007/s10555-006-7886-9 Xing, 2017, Development and validation of a serum biomarker panel for the detection of esophageal squamous cell carcinoma through RNA transcriptome sequencing, J Cancer, 8, 2346, 10.7150/jca.19465 Sedighi, 2016, Matrix metalloproteinase-13 - a potential biomarker for detection and prognostic assessment of patients with esophageal squamous cell carcinoma, Asian Pac J Cancer Prev, 17, 2781 Zhou, 2011, Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma, J Clin Oncol, 29, 4781, 10.1200/JCO.2011.38.2697 Cohen, 2018, Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, 359, 926, 10.1126/science.aar3247 Patz, 2007, Panel of serum biomarkers for the diagnosis of lung cancer, J Clin Oncol, 25, 5578, 10.1200/JCO.2007.13.5392 Sechopoulos, 2021, Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: state of the art, Semin Cancer Biol, 72, 214, 10.1016/j.semcancer.2020.06.002 Mitsala, 2021, Artificial intelligence in colorectal cancer screening, diagnosis and treatment. A new era, Curr Oncol, 28, 1581, 10.3390/curroncol28030149 Pantanowitz, 2020, An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study, Lancet Digit Health, 2, e407, 10.1016/S2589-7500(20)30159-X Cristiano, 2019, Genome-wide cell-free DNA fragmentation in patients with cancer, Nature, 570, 385, 10.1038/s41586-019-1272-6 Wan, 2019, Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA, BMC Cancer, 19, 832, 10.1186/s12885-019-6003-8